

Rustem A Gafanov

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6028514/rustem-a-gafanov-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

12
papers

1,581
citations

5
h-index

16
g-index

16
ext. papers

2,421
ext. citations

6.6
avg, IF

4.12
L-index

#	Paper	IF	Citations
12	Chemoimmunotherapy in urothelial cancer: concurrent or sequential?. <i>Onkourologiya</i> , 2022 , 17, 124-128	0.5	
11	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1029-1039	2.7	43
10	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1020-1028	2.2	26
9	KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021 , 17, 3291-3299	3.6	5
8	Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 983-988	7.4	8
7	Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?. <i>Onkourologiya</i> , 2020 , 16, 29-37	0.5	
6	An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia. <i>Onkourologiya</i> , 2020 , 16, 90-101	0.5	1
5	Choice of treatment options for metastatic hormone-sensitive prostate cancer. <i>Meditinskiy Sovet</i> , 2020 , 90-99	0.4	
4	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1563-1573	21.7	165
3	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 380, 1116-1127	59.2	1327
2	Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection. <i>Onkourologiya</i> , 2019 , 14, 139-149	0.5	2
1	Experience of using atezolizumab in 1st line therapy of metastatic urothelial cancer. <i>Onkourologiya</i> , 2019 , 15, 113-119	0.5	